612-3SBio

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug Name612-3SBio

Drug Alias Name612-3SBio

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsReceptor protein-tyrosine kinase erbB-2 antagonistsT lymphocytes stimulants

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator Companies3sbio Inc

China Registration ClassN/A

Develop Information

Active Companies3sbio Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A